Does Thyroid Recover After Immunotherapy?

Thyroid recovery after immunotherapy depends heavily on which type of thyroid dysfunction develops and how severely the gland is damaged. The initial overactive phase (thyrotoxicosis) that many patients experience tends to resolve on its own within weeks, but the underactive phase (hypothyroidism) that often follows is frequently permanent, with roughly half of immune-related endocrine side effects proving irreversible. That said, the picture is not uniformly bleak: a meaningful fraction of patients do see their thyroid normalize, and several factors can help predict which way things will go.

How Immunotherapy Disrupts the Thyroid

Immune checkpoint inhibitors work by releasing the brakes on your immune system so it can attack cancer cells more aggressively. The trade-off is that unleashed immune cells sometimes turn on healthy tissue, and the thyroid gland is one of their favorite targets. T cells appear to be the main culprits, infiltrating the thyroid and triggering inflammation that damages the gland’s ability to produce hormones properly.¹

The resulting thyroiditis typically unfolds in a predictable two-act pattern. First, the inflamed gland dumps stored thyroid hormone into the bloodstream, causing a temporary hyperthyroid phase. Then, once the gland’s hormone reserves are depleted and its cells are damaged, production drops and hypothyroidism sets in. In one study, this classic sequence of overactivity followed by underactivity occurred in about three-quarters of affected patients, while the remaining quarter skipped straight to hypothyroidism without ever passing through the hyperthyroid stage.²

How common is this? Estimates vary widely depending on the drug and how closely patients are monitored. Rates of hypothyroidism have been reported anywhere from a few percent to around 40% of patients receiving checkpoint inhibitors, with the higher figures likely reflecting more comprehensive thyroid screening.³ Anti-PD-1 drugs like nivolumab and pembrolizumab seem to carry a higher risk than anti-CTLA-4 drugs like ipilimumab, with one analysis reporting thyroid dysfunction in about 7.5% of melanoma patients on anti-PD-1 therapy compared with 3.6% on anti-CTLA-4 treatment.⁴

The Hyperthyroid Phase Usually Resolves

If you develop the initial overactive thyroid phase, the good news is that it almost always burns out on its own. In a review of pembrolizumab-induced thyroiditis, patients who went through transient thyrotoxicosis returned to normal thyroid function in a median of about six and a half weeks, and none required antithyroid medications or steroids.⁵ Another study found the thyrotoxic phase lasted a median of six weeks, with about two-thirds of patients reporting no symptoms at all during that window.⁶

When symptoms do appear, they tend to be mild: a faster heart rate, feeling jittery or warm, mild weight loss. A beta-blocker is sometimes prescribed for comfort during this stretch, but the underlying thyrotoxicosis resolves without direct treatment in the vast majority of cases. An early study of patients on PD-1 therapy confirmed that all six patients with thyrotoxicosis saw it resolve spontaneously, though each one subsequently developed hypothyroidism.⁷ That transition is the critical part: just because the hyperthyroid phase ends does not mean the thyroid has healed. Often it has simply exhausted its remaining hormone stores.

Hypothyroidism Is the More Stubborn Problem

The hypothyroid phase is where the question of true recovery gets complicated. Once the thyroid gland has been sufficiently damaged by immune-mediated inflammation, it may no longer produce enough hormone on its own. In a large single-center study of over 1,300 patients, more than half of those who developed overt hyperthyroidism went on to develop overt hypothyroidism within a median of about one and a half months. About a third of overt hypothyroidism cases appeared without any preceding hyperthyroid phase at all.⁸

Broadly, immune-related endocrine toxicities are irreversible in about half of cases.⁹ For hypothyroidism specifically, permanent cases seem to be more common than transient ones. In a study that followed 124 patients who developed thyroid problems on checkpoint inhibitors, those who ended up with permanent hypothyroidism actually showed earlier onset of thyrotoxicosis (around 42 days from the first dose) compared with those whose thyroid function eventually normalized (around 56 days).¹⁰ The earlier and more aggressive the immune attack on the gland, the less tissue survives to bounce back.

That said, subclinical thyroid dysfunction, where lab values drift mildly outside normal but symptoms are absent or minimal, has a better track record. The same large UK study found that subclinical thyroid dysfunction returned directly to normal in up to half of patients.⁸ So the severity of the initial dysfunction matters: mild cases have a reasonable chance of self-correcting, while overt hypothyroidism is more likely to stick around and require lifelong thyroid hormone replacement.

What Predicts Whether Your Thyroid Will Recover

Researchers have identified several factors that help predict who ends up with permanent thyroid damage and who bounces back.

Pre-existing thyroid antibodies are one of the strongest warning signs. People who already have detectable antibodies against thyroid peroxidase (anti-TPO) before starting immunotherapy are significantly more likely to develop overt hypothyroidism. One study found anti-TPO antibodies in a third of patients who went on to develop overt hypothyroidism, compared with just 4% of those who did not.¹¹ A prediction model incorporating baseline TSH, thyroglobulin antibodies, TPO antibodies, and platelet count was able to identify patients at higher risk for thyroid problems before treatment even began.¹²

Genetics play a role too. Certain HLA types, the immune-system genes that help determine which molecules your immune cells react to, appear to predispose people toward persistent thyroid dysfunction. One Japanese study found that specific HLA alleles (HLA-DPA1*01:03 and HLA-DPB1*02:01) were significantly more common in patients whose thyroid dysfunction became permanent compared with those whose thyroid recovered. The same study confirmed that pre-existing autoimmunity and the severity of the initial dysfunction helped differentiate persistent from temporary cases.¹³

In pediatric patients, thyroid recovery appears to be particularly uncommon, with European guidelines noting that the recovery rate is “poor.”¹⁴ Recovery from hypothyroidism in children on checkpoint inhibitors is only rarely reported.¹⁵

Combination Therapy and Newer Drugs

The type of immunotherapy regimen influences both the risk and the timeline. Combination treatments, which pair a PD-1 inhibitor with another checkpoint inhibitor like ipilimumab, tend to cause thyroid dysfunction earlier and more frequently. In one study, combination therapy triggered thyroid problems in as little as three weeks, while monotherapy patients developed issues at a median of nine weeks. The duration of the hyperthyroid phase, however, was similar regardless of which regimen was used.² A large cohort study found that more than half of patients receiving combination checkpoint inhibitors developed hyperthyroidism, a substantially higher rate than with monotherapy.⁸

Newer combination regimens are expanding the concern. Nivolumab combined with relatlimab, a LAG-3 inhibitor, carries a significantly increased risk of hypothyroidism and thyroiditis compared with nivolumab alone.¹⁶ In one analysis of patients receiving this combination, several developed thyroiditis that progressed to hypothyroidism requiring hormone replacement, though at least one patient with central hypothyroidism was able to discontinue thyroid hormone after about two months once the thyroid axis recovered.¹⁷ That last detail is worth noting: central hypothyroidism, caused by problems in the pituitary gland rather than the thyroid itself, has a different recovery trajectory than primary hypothyroidism, where the thyroid tissue is directly destroyed.

Central Versus Primary Hypothyroidism

This distinction matters more than most patients realize. Checkpoint inhibitors can cause thyroid underactivity through two very different mechanisms. Primary hypothyroidism happens when immune cells attack the thyroid gland directly. Central (or secondary) hypothyroidism occurs when the pituitary gland, which sits at the base of the brain and sends signals telling the thyroid how much hormone to make, is damaged by immune-mediated hypophysitis.

Recovery prospects differ substantially between the two. In a study of patients with checkpoint-inhibitor-induced hypophysitis, about 24% achieved complete thyroid axis recovery, with recovery time ranging from 15 weeks to over a year. Across different studies, the recovery rate for the thyroid axis in hypophysitis ranged from 5% to 100%, a wild spread that reflects differences in study populations, drug regimens, and how aggressively pituitary damage was treated.¹⁸ The adrenal axis, for comparison, recovers far less often, meaning patients whose pituitary is affected usually need ongoing steroid replacement even if their thyroid function bounces back.

The Glucocorticoid Question

One intriguing finding is a possible connection between glucocorticoid (steroid) exposure and thyroid recovery. A retrospective study of melanoma patients on checkpoint inhibitors found that glucocorticoid use was significantly associated with thyroid recovery: among patients whose thyroid function recovered, 6 out of 7 had been exposed to glucocorticoids, compared with just 3 out of 10 in the non-recovery group.¹⁹

This does not mean steroids should be routinely prescribed to protect the thyroid. Steroids could dampen the same immune response that makes immunotherapy effective against cancer. The observation is also from a small, retrospective dataset and could reflect confounding factors. But it raises interesting questions about whether early anti-inflammatory intervention might preserve thyroid tissue in select patients. Clinical practice currently reserves high-dose steroids for severe immune-related side effects in other organ systems, and mild-to-moderate thyroid dysfunction is typically managed with hormone replacement rather than immunosuppression.

Imaging Can Show the Damage in Real Time

If there is any ambiguity about whether thyroid dysfunction is active or has already burned out, imaging can help. During the active inflammatory phase, PET/CT scans often show increased metabolic activity in the thyroid, a sign that the gland is under attack. Neck CT may reveal a swollen, less-dense gland, sometimes with areas of tissue death visible as ring-shaped enhancement patterns. Once the inflammation subsides and the gland has been damaged, follow-up imaging typically shows the opposite: a shrunken, atrophied gland that correlates with the clinical picture of permanent hypothyroidism.²⁰ For patients whose doctors are weighing whether to attempt weaning off thyroid hormone replacement, imaging evidence of gland atrophy essentially answers the question: a shrunken gland is not coming back.

Thyroid Dysfunction May Signal Better Cancer Outcomes

Perhaps the most counterintuitive finding in this space is that developing thyroid problems on immunotherapy appears to be a good sign for cancer treatment. Multiple meta-analyses have consistently shown that patients who develop thyroid dysfunction during checkpoint inhibitor therapy have significantly better progression-free survival and overall survival than those whose thyroid remains unaffected.

One meta-analysis focused on non-small-cell lung cancer found that patients with immunotherapy-related thyroid dysfunction had a 66% lower risk of death and a 46% lower risk of disease progression.²¹ A broader meta-analysis spanning multiple cancer types found a similar pattern, with thyroid side effects linked to improved overall survival and progression-free survival even after accounting for potential time-related biases.²² A large two-center study of over 700 lung cancer patients confirmed the association, finding that thyroid side effects occurred in about 13% of patients and were linked to better progression-free survival.²³

The explanation that fits best is that thyroid dysfunction is a marker of a more vigorous immune response overall. If your immune system is active enough to attack your own thyroid, it is probably also doing a more thorough job of attacking the cancer. Interestingly, the study comparing permanent hypothyroidism with transient thyroid dysfunction found that permanent hypothyroidism was associated with even better survival, suggesting that a stronger, more sustained immune response against the thyroid correlates with a stronger response against the tumor.¹⁰

Living with Thyroid Replacement After Immunotherapy

For patients whose thyroid does not recover, the practical reality is a daily thyroid hormone pill, typically levothyroxine. This is the same medication used by the millions of people with autoimmune thyroid disease (Hashimoto’s) unrelated to cancer treatment, and it is inexpensive, well tolerated, and effective at restoring normal hormone levels. Cancer centers generally do not stop immunotherapy because of thyroid dysfunction; the replacement hormone manages the side effect while the checkpoint inhibitor continues doing its job against the tumor.¹⁴

Whether you stay on replacement permanently depends on periodic reassessment. Some oncologists will attempt to taper or stop levothyroxine after immunotherapy is completed, particularly in patients whose hypothyroidism was mild or subclinical. A study of long-term ipilimumab survivors noted that several patients were successfully weaned off thyroid hormone with subsequent normalization of thyroid function, though others required ongoing replacement for the duration of follow-up.²⁴ The decision to try weaning usually involves checking thyroid function labs at regular intervals and looking for signs that the gland is producing hormone on its own again. If TSH rises when the replacement dose is lowered, the gland has not recovered enough to go it alone.

When Monitoring Matters Most

Thyroid function tests before each immunotherapy cycle, or at least every four to six weeks for the first several months, are standard practice at most cancer centers. The value of this monitoring is not just catching dysfunction early, but distinguishing between subclinical changes that might resolve and overt dysfunction that needs treatment. Given that subclinical cases return to normal about half the time, not every abnormal lab result means a patient is headed for permanent replacement therapy. Watching the trend over a few weeks is often more informative than reacting to a single abnormal value.

For patients who have completed immunotherapy and are on thyroid replacement, continued monitoring still matters. Thyroid needs can shift as overall health and body weight change during cancer recovery, and the rare patient whose gland function returns can end up overmedicated if no one checks. The timeline for possible recovery extends well beyond the end of immunotherapy itself. Some patients in the hypophysitis recovery studies did not see thyroid axis normalization for nearly a year.¹⁸ Patience and regular blood work are the practical tools that separate patients who genuinely need lifelong replacement from those who can eventually stop.

1
Frontiers in Endocrinology. Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
2
Endocr Connections. Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
3
The Egyptian Journal of Internal Medicine. Immunotherapy-induced thyroid dysfunction: an updated review
4
PubMed Central. Thyroid dysfunctions secondary to cancer immunotherapy
5
The Journal of Clinical Endocrinology & Metabolism. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
6
PubMed Central. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
7
The Journal of Clinical Endocrinology & Metabolism. Induction of Painless Thyroiditis in Patients Receiving Programmed Death 1 Receptor Immunotherapy for Metastatic Malignancies
8
PubMed Central. Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort
9
PubMed. Thyroid disorders induced by checkpoint inhibitors
10
Frontiers in Endocrinology. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival
11
Endocrinology and Metabolism. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
12
PubMed. Development and Validation of a Prediction Model for Thyroid Dysfunction in Patients During Immunotherapy
13
Endocrine Journal. Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors
14
PubMed Central. Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibitors
15
Hormone Research in Paediatrics. Endocrine-Related Adverse Conditions in Pediatric Patients Treated with Immune Checkpoint Inhibition for Malignancies
16
PubMed. Safety profile of nivolumab-relatlimab in cancer patients: a living pharmacovigilance study of clinical trials and postmarketing data (version 1.0)
17
The Journal of Clinical Endocrinology & Metabolism. The Risk of Adrenal Insufficiency After Treatment With Relatlimab in Combination With Nivolumab is Higher Than Expected
18
Endocrine-Related Cancer. Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
19
Endocrine Practice. Thyroid Dysfunction, Recovery, and Prognosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors
20
Exploration of Targeted Anti-tumor Therapy. A case of immunotherapy-induced thyroiditis
21
PubMed Central. Immune-related thyroid dysfunction is associated with improved long-term prognosis in patients with non-small cell lung cancer treated with immunotherapy
22
PubMed Central. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
23
PubMed Central. Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer
24
Cancer Immunology Research. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities Health Outcomes and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center